Medtronic Issues UK Warning On Implantable Pump Safety
Executive Summary
The field safety notice revealed two patient deaths and five incidents of over-infusion tied to Medtronic's SynchroMed II pump. The pump was removed from the US market under a 2015 consent decree.
You may also be interested in...
Market Intel: Insulin Pumps Dominate $7bn-Plus Global Infusion Devices Market
The global infusion drug delivery market continues to be driven by the rising prevalence of chronic disease and associated obesity, coupled with a growing aging population. Technological advancements such as less invasive pumps, needlestick prevention features and miniaturization have also supported the growing demand, but obstacles such as safety and security issues remain. According to a new report by Meddevicetracker, the global market for infusion pumps and disposables will reach $9.9bn by 2022, a CAGR of 6.4% from 2017. This article takes an in-depth look at the overall infusion pumps market, and dives deeper into the three fastest-growing segments – insulin, enteral and disposable pumps – highlighting the key players and competitive landscape.
SynchroMed brings no pain relief for Medtronic
Medtronic has agreed to the US FDA’s demands to stop making and distributing the SynchroMed II implantable infusion pumps, except in limited circumstances, until the company corrects quality system violations identified by the agency.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.